Literature DB >> 6629343

Prognosis in patients with thin malignant melanoma: influence of regression.

V J McGovern, H M Shaw, G W Milton.   

Abstract

It has been suggested that patients with thin malignant melanoma displaying evidence of histological regression may have a poor prognosis. In the present study, the case histories of 353 patients with clinical stage I cutaneous malignant melanoma up to 0.7 mm thick were reviewed to determine if either active or past regression in these lesions was a poor prognostic sign. Lesions were reported as displaying evidence of partial regression if either (a) a portion of the melanoma had a heavy lymphocytic infiltrate associated with loss of tumour cells or the presence of degenerating tumour cells, or (b) a portion of the melanoma was replaced by vascular fibrous tissue with or without pigment-containing phagocytes. The incidence of regression in this study (58%) was similar to that reported in another recent large study on thin lesions (53%). Only slightly more regressed than unregressed lesions metastasized (8% versus 5% respectively). A high proportion of first recurrences from these thin lesions developed at sites remote from the primary lesion (lung, bone or in subcutaneous tissues or lymph nodes wide of the line of spread). However, the presence or absence of regression in thin lesions did not appear to influence the site of first recurrence. Cumulative 10-year survival rates for patients whose lesions displayed or did not display evidence of either active or past regression were nearly identical.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1983        PMID: 6629343     DOI: 10.1111/j.1365-2559.1983.tb02279.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  18 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

4.  A negative skin biopsy for malignancy does not exclude the possibility of subsequent fatal disease.

Authors:  J Jacob; C A Austin; D N Slater
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

5.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

6.  High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Authors:  Sook Jung Yun; Phyllis A Gimotty; Wei-Ting Hwang; Peter Dawson; Patricia Van Belle; David E Elder; Rosalie Elenitsas; Lynn Schuchter; Paul J Zhang; DuPont Guerry; Xiaowei Xu
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

7.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

8.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

9.  Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator.

Authors:  J W Kelly; R W Sagebiel; S Clyman; M S Blois
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

10.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.